Clinical trial

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

NCT02906163

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-10-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2016-10-01Date precision: month

Registry last updated2016-09-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

EGFR Mutation Positive Non Small Cell Lung Cancerunresolved

Interventions

Thymalfasin (Thymosin alpha 1, Ta1)DRUG

SoC (tyrosine kinase inhibitor)DRUG

Sponsors & collaborators

SciClone Pharmaceuticalslead sponsor

Mapped research locations

RomeItaly2 MilanItaly1 TorinoItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02906163 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.